We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+16.48%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$11.7B
AUM Growth
+$1.25B
Cap. Flow
-$79.9M
Cap. Flow %
-0.68%
Top 10 Hldgs %
34.47%
Holding
156
New
27
Increased
33
Reduced
24
Closed
20

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$208M
2
ACT.PRA
ACTAVIS PLC Pfd Conv Ser A (Irl)
ACT.PRA
+$109M
3
BMY icon
Bristol-Myers Squibb
BMY
+$74.8M
4
BLUE
bluebird bio
BLUE
+$56.1M
5
CAH icon
Cardinal Health
CAH
+$54.7M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$191M
2
AGN
Allergan Inc
AGN
+$158M
3
MRK icon
Merck
MRK
+$149M
4
BIIB icon
Biogen
BIIB
+$113M
5
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$106M

Sector Composition

Rank Sector Weight
1 Healthcare 83.37%
2 Technology 0.15%
3 Financials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AET
101
DELISTED
Aetna Inc
AET
$10M 0.09%
94,000
– –
RDHL
102
Redhill Biopharma
RDHL
$4.26M
$9.98M 0.09%
686
+80
+13% +$1.14M
ONCE
103
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$9.84M 0.08%
+127,000
New +$7.31M
ABT icon
104
Abbott
ABT
$191B
$9.78M 0.08%
211,000
– –
MDXG icon
105
MiMedx Group
MDXG
$645M
$8.7M 0.07%
836,800
– –
ARRY
106
CALL
DELISTED
Array Biopharma Inc
ARRY
$8.11M 0.07%
+1,100,000
New +$7.83M
NVTA
107
DELISTED
Invitae Corporation
NVTA
$7.65M 0.07%
+456,666
New +$8.46M
ALIM
108
DELISTED
Alimera Sciences
ALIM
$7.51M 0.06%
100,000
– –
CTRX
109
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
$7.14M 0.06%
+120,000
New +$6.1M
SUPN icon
110
Supernus Pharmaceuticals
SUPN
$2.75B
$7.01M 0.06%
580,000
– –
ADXS
111
DELISTED
Advaxis Inc
ADXS
$6.21M 0.05%
+28,673
New +$4.41M
DVA icon
112
DaVita
DVA
$15.5B
$6.18M 0.05%
76,000
– –
IPXL
113
CALL
DELISTED
Impax Laboratories, Inc.
IPXL
$4.69M 0.04%
100,000
-50,000
-33% -$1.99M
DRNA
114
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$4.69M 0.04%
+195,000
New +$4.39M
SNN icon
115
CALL
Smith & Nephew
SNN
$13.7B
$3.42M 0.03%
+100,000
New +$3.54M
FATE icon
116
Fate Therapeutics
FATE
$267M
$3.39M 0.03%
692,900
– –
EHTH icon
117
eHealth
EHTH
$42.2M
$2.56M 0.02%
+273,100
New +$3.26M
DSCI
118
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$2.54M 0.02%
300,000
– –
BLRX
119
BioLineRX
BLRX
$12.3M
$2.4M 0.02%
1,892
– –
AKRX
120
CALL
DELISTED
Akorn Inc
AKRX
$2.38M 0.02%
+50,000
New +$2.27M
QLTI
121
CALL
DELISTED
QLT Inc
QLTI
$1.96M 0.02%
+500,000
New +$2.06M
XTNT icon
122
Xtant Medical Holdings
XTNT
$59.1M
$1.95M 0.02%
39,620
– –
IMUX icon
123
PUT
Immunic
IMUX
$175M
$1.88M 0.02%
+188
New +$1.73M
CRIS icon
124
Curis
CRIS
$9.82M
$1.74M 0.01%
362
-613
-63% -$2.96M
CEMP
125
DELISTED
Cempra, Inc.
CEMP
$1.72M 0.01%
50,000
– –
2 3 4
5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q1 2015 Portfolio in Review

As of Q1 2015, OrbiMed held 156 positions worth $11.7B, up 12% from $10.5B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed's Q1 2015 filing shows 27 new, 33 increased, 24 reduced and 20 closed positions. Its largest new stake was ACTAVIS PLC Pfd Conv Ser A (Irl): 104,200 shares worth $105M. The largest sale was Vertex Pharmaceuticals, an estimated $191M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 86% a quarter earlier, followed by Technology and Financials.

  • OrbiMed's largest Q1 2015 buy was ACTAVIS PLC Pfd Conv Ser A (Irl): 104,200 shares worth $105M.
  • OrbiMed added most to Boston Scientific in Q1 2015, an estimated $208M increase.
  • OrbiMed's biggest Q1 2015 reduction was Vertex Pharmaceuticals, cutting an estimated $191M.
  • OrbiMed fully exited Allergan Inc in Q1 2015, selling an estimated $158M.
  • OrbiMed's ten largest holdings make up 34% of its $11.7B portfolio in Q1 2015.
  • OrbiMed opened 27 new positions and closed 20 in Q1 2015.
  • OrbiMed's portfolio value rose 12% quarter-over-quarter to $11.7B.

Based on OrbiMed's 13F filing for Q1 2015, filed 15 May 2015.